ANDA 83743, held by Chartwell Molecular. Quinidine Sulfate.
As of Nov 21, 2026, ANDA 83743 (Quinidine Sulfate), held by Chartwell Molecular, was first approved by FDA on Jan 14, 1977, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 14, 1977 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Quinidine Sulfate200MG · tablet;oral | Quinidine Sulfate | Discontinued |
| Aug 21, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 8, 1982 | Supplement 2Manufacturing | Approved | None posted |
| Apr 8, 1982 | Supplement 3Manufacturing | Approved | None posted |
| Jan 14, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters